Citi: Sino Biopharmaceutical (01177) Enhances Out-Licensing Potential with siRNA Firm Acquisition, Sets HK$10.8 Target Price and 'Buy' Rating

Intelligent Financial APP learned that Citi issued a research report stating that Sino Biopharmaceutical Co., Ltd. (01177) announced the acquisition of Hygieia, a private biotechnology company focused on small interfering nucleic acid drugs (siRNA), for a maximum basic consideration of 1.2 billion yuan.The bank believes that this acquisition further enhances Sino Biopharm's innovation capabilities and out-licensing potential, solidifying its position as a leader among China's innovative pharmaceutical companies; it now assigns a target price of HK$10.8 and a "Buy" rating.

Hygieia has developed multiple differentiated delivery platforms, with its R&D pipeline including candidate drugs such as Kylo-11, Kylo-12, Kylo-0603, HJY-10, and HJY-02. Through this acquisition, Sino Biopharm will establish a new generation of innovative cardiovascular pipelines, strengthen its presence in weight management and metabolic diseases, and expand into the new frontier of chronic disease management.